MeritValue

BioCorRx Inc.

BICXdata completeness 75%16 fiscal years on file

Data notes: no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$48,2721$213,8412$89,1603$7,6654$797,2444
Net income−$5.21M5−$4.38M6−$3.77M7−$5.11M8−$3.44M8
Operating cash flow−$3.54M9−$2.04M10−$1.85M11−$1.1M12−$2.3M12
Capital expenditure$2,01713$013———
Free cash flow (derived)−$3.54M9−$2.04M10———
Total debt$131,44014$014———
Cash & equivalents$85,83815$68,61516$65,22217$88,03317$139,36017
Diluted shares1.1M1.4M2.7M10.5M18.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$6.07
your share of equity
Profit it earned you last year
−$1.86
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$6.07 of net worth that earned you −$1.86 last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+1652% shares · 5y

Share count is up 1652% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has fallen 100% — deleveraging.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.5.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001477932-23-002039 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001477932-24-001705 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001477932-25-002219 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001477932-26-001807 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001477932-23-002039 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001477932-24-001705 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001477932-25-002219 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001477932-26-001807 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001477932-23-002039 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001477932-24-001705 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001477932-25-002219 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001477932-26-001807 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2021-12-31 · accession 0001477932-23-002039 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2021-12-31 · accession 0001477932-23-002039 (LongTermDebt)
  15. 10-K · period ending 2021-12-31 · accession 0001477932-24-001705 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  16. 10-K · period ending 2022-12-31 · accession 0001477932-25-002219 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  17. 10-K · period ending 2023-12-31 · accession 0001477932-26-001807 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)